Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

X-Vax Technology
601 Heritage Drive, Suite 138
Jupiter, FL 33458

We are a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we are taking could succeed in defeating herpes. We have created a herpes vaccine candidate that we call ˆ†gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, we have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models-with encouraging results. The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells. 6, 7

Key Contact
Ulf Wiinberg
President & CEO
Funding Events

07/23/19 $56,000,000 Series A Adjuvant Capital
Alexandria Venture Investments
Founders Fund
Johnson & Johnson Innovation
Serum Institute of India

Featured Reading